The mRNA Monthly—June 2025 Edition

"The Evolving Needs of Therapeutic mRNA Developers" text over green background and DNA strand.

Advancements in Biopharma Spur Innovation

Christian Cobaugh, chief scientific officer and founder of Vernal Biosciences, offered PharmaTech editor Susan Haigney comments about where he believes mRNA and LNP advancements fit into the biopharm innovation landscape.

Source: Pharmaceutical Technology, June 2025, Volume 49, Issue 5, Pages: 12-15

Read Article


"The Evolving Needs of Therapeutic mRNA Developers" text over green background and DNA strand.

Well-Defined mRNA Platform Processes & Collaboration Advanced a Novel Gene Therapy in Jeopardy

Learn how Vernal Bio changed the course of a stalled cancer gene therapy program, pairing proven mRNA platform methods with scientific flexibility and hands-on collaboration.

Access Case Study


"The Evolving Needs of Therapeutic mRNA Developers" text over green background and DNA strand.

The Advent of Clinical Self-Amplifying RNA Vaccines

By enabling intracellular amplification of RNA, self-amplifying RNA (saRNA) facilitates robust antigen expression at lower doses, enhancing immunogenicity and cost-effectiveness.

Source: Molecular Therapy, Volume 33, Issue 6, 4 June 2025, Pages 2565-2582

Explore Article


"The Evolving Needs of Therapeutic mRNA Developers" text over green background and DNA strand.

Data Over Doubt—The Scientific Case for mRNA in Cancer Care

mRNA-based therapies—through reprogramming myeloid cells and enabling in vivo CAR approaches—offer promise for faster, safer, and more affordable solutions for solid tumors. He emphasizes the criticality of data-reliant approaches, urging science‑driven oncology.

Source: Genetic Engineering & Biotechnology News, Daniel Getts, PhD, June 6, 2025

Read Article


"The Evolving Needs of Therapeutic mRNA Developers" text over green background and DNA strand.

mRNA-LNPs Induce Immune Activation and Cytokine Release in Human Whole Blood Assays Across Diverse Health Conditions

Understanding the immunomodulatory effects of novel mRNA-LNPs is crucial for future therapeutic development. An in vitro whole blood assay was developed to assess the impact of mRNA-LNPs on immune cell function, cytokine release, and complement activation. mRNA-LNPs significantly increased CD69 expression on T cells and natural killer cells, and CD80/CD86 on myeloid subsets, in a dose-dependent fashion.

Source: Molecular Therapy, Volume 33, Issue 6, p2872-2885, June 04, 2025

Check It Out


"The Evolving Needs of Therapeutic mRNA Developers" text over green background and DNA strand.

A Simpler Process for mRNA Purification

Scientists from MIT say they have developed a more straightforward process for messenger RNA (mRNA) purification based on continuous precipitation.

Source: Genetic Engineering and Biotechnology News, Vivienne Raper PhD, June 4, 2025 Credit: Genetic Engineering and Biotechnology News (Kitsawet Saethao/Getty Images)

Learn More